多索茶碱联合沙美特罗替卡松对慢阻肺患者炎性因子及血气分析指标的影响
|
摘要
目的探究多索茶碱联合沙美特罗替卡松对慢性阻塞性肺疾病(COPD)患者炎性因子及血气分析指标的影响。方法选取2016年2月至2018年2月本院收治的COPD患者150例,随机分为观察组(75例)与对照组(75例)。对照组接受沙美特罗替卡松吸入治疗,在此基础上,观察组加施多索茶碱治疗。比较两组治疗效果、炎性因子、肺功能及血气分析指标水平的差异。结果观察组临床疗效明显高于对照组(P<0.05);治疗后,观察组炎性因子IL-5明显低于对照组,而IL-12则高于对照组(P<0.05);观察组血气指标PaO2明显高于对照组,而PaCO2则低于对照组(P<0.05);观察组肺功能指标FVC、FEV1、PEF均明显高于对照组(P<0.05)。结论多索茶碱联合沙美特罗替卡松可有效改善COPD患者肺功能及动脉血气,纠正体内Thl/Th2失衡,疗效显著,值得临床推荐。
Objective To investigate the effects of doxofylline combined with salmeterol and fluticasone on inflammatory factors and blood gas analysis in patients with chronic obstructive pulmonary disease(COPD). Methods 150 COPD patients admitted to our hospital from February 2016 to February 2018 were randomly divided into observation group(75 cases) and control group(75 cases). The control group was treated with salmeterol and fluticasone inhalation, and the observation group was treated with doxofylline. The therapeutic effect, inflammatory factors, pulmonary function and blood gas analysis indexes were compared between the two groups. Results The clinical efficacy of the observation group was significantly higher than that of the control group(P<0.05); after treatment, the inflammatory factor IL-5 of the observation group was significantly lower than that of the control group, while IL-12 was higher than that of the control group(P<0.05); the blood gas index PaO2 of the observation group was significantly higher than that of the control group, while PaCO2 was lower than that of the control group(P<0.05); the lung function index FVC, FEV1 and PEF of the observation group were significantly higher than that of the control group(P<0.05). Conclusion Doxofylline combined with salmeterol and fluticasone can effectively improve the pulmonary function and arterial blood gas of COPD patients, and correct the imbalance of Thl/Th2 in vivo. The curative effect is remarkable and worthy of clinical recommendation.
Objective To investigate the effects of doxofylline combined with salmeterol and fluticasone on inflammatory factors and blood gas analysis in patients with chronic obstructive pulmonary disease(COPD). Methods 150 COPD patients admitted to our hospital from February 2016 to February 2018 were randomly divided into observation group(75 cases) and control group(75 cases). The control group was treated with salmeterol and fluticasone inhalation, and the observation group was treated with doxofylline. The therapeutic effect, inflammatory factors, pulmonary function and blood gas analysis indexes were compared between the two groups. Results The clinical efficacy of the observation group was significantly higher than that of the control group(P<0.05); after treatment, the inflammatory factor IL-5 of the observation group was significantly lower than that of the control group, while IL-12 was higher than that of the control group(P<0.05); the blood gas index PaO2 of the observation group was significantly higher than that of the control group, while PaCO2 was lower than that of the control group(P<0.05); the lung function index FVC, FEV1 and PEF of the observation group were significantly higher than that of the control group(P<0.05). Conclusion Doxofylline combined with salmeterol and fluticasone can effectively improve the pulmonary function and arterial blood gas of COPD patients, and correct the imbalance of Thl/Th2 in vivo. The curative effect is remarkable and worthy of clinical recommendation.
引文
[1]王彬,赵光强,柴芳,乌司他丁在慢阻肺疾病急性发作中的应用及对炎性因子的影响研究[J].临床肺科杂志,2016,8(3):422-425.
[2]严瑾,金晓燕.二药联合对稳定期慢性阻塞性肺疾病的治疗价值[J].临床肺科杂志,2015,13(7):1284-1287.
[3]郁震,曹娟,王红梅,等.噻托溴铵联合沙美特罗替卡松对慢阻肺急性加重期患者免疫功能的影响[J].临床肺科杂志,2016,21(5):795-798.
[4]徐兴婷,吴倩,段琼,等.慢阻肺急性加重期肺功能与血气分析、炎症指标相关性研究[J].临床肺科杂志,2015,10(5):860-862.
[5]陈洋,张军营,倪高顺.环丙沙星联合茶碱类药物治疗慢阻肺的临床效果分析[J].陕西医学杂志,2017,46(12):1779-1780.
[6]康建军,孙秀娥.多索茶碱与噻托溴铵粉联合治疗慢阻肺对肺功能的影响研究[J].湖南中医药大学学报,2016,10(a2):908-909.
[7]张金龙,谭亚萍,叶青,等.沙美特罗/氟替卡松吸入剂(舒利迭)在慢性阻塞性肺疾病中的使用情况[J].临床肺科杂志,2015,11(9):1684-1686.
[8]张向红.沙美特罗替卡松对照噻托溴铵联合沙美特罗替卡松治疗慢阻肺稳定期的观察[J].中国医药导刊,2012,8(11):445-447.
[9]曾林淼,俞晓莲,叶凯龙,等.沙美特罗替卡松联合噻托溴铵与单用沙美特罗替卡松治疗我国慢性阻塞性肺疾病患者的Meta分析[J].中国呼吸与危重监护杂志,2017,3(6):545-554.
[10]朱卫波.甲强龙联合多索茶碱对慢性阻塞性肺病患者血清脂联素、MMP-9、IL-17、IL-10及TNF-α水平的影响[J].海南医学院学报,2016,22(12):1214-1216.
[11]陈伦音,王颖峰,贺珊珊,等.参芪扶正注射液辅助纳洛酮与BiPAP呼吸机治疗对AECOPD伴Ⅱ型呼吸衰竭患者血清炎性因子、免疫功能及血气分析指标的影响[J].海南医学院学报,2017,23(16):2176-2179.
[12]张娟,左昔清,章建良,等.慢性阻塞性肺疾病合并呼吸衰竭患者Th1/Th2变化趋势及中医辨证治疗对其影响的研究[J].中华中医药学刊,2016,48(2):451-455.
[2]严瑾,金晓燕.二药联合对稳定期慢性阻塞性肺疾病的治疗价值[J].临床肺科杂志,2015,13(7):1284-1287.
[3]郁震,曹娟,王红梅,等.噻托溴铵联合沙美特罗替卡松对慢阻肺急性加重期患者免疫功能的影响[J].临床肺科杂志,2016,21(5):795-798.
[4]徐兴婷,吴倩,段琼,等.慢阻肺急性加重期肺功能与血气分析、炎症指标相关性研究[J].临床肺科杂志,2015,10(5):860-862.
[5]陈洋,张军营,倪高顺.环丙沙星联合茶碱类药物治疗慢阻肺的临床效果分析[J].陕西医学杂志,2017,46(12):1779-1780.
[6]康建军,孙秀娥.多索茶碱与噻托溴铵粉联合治疗慢阻肺对肺功能的影响研究[J].湖南中医药大学学报,2016,10(a2):908-909.
[7]张金龙,谭亚萍,叶青,等.沙美特罗/氟替卡松吸入剂(舒利迭)在慢性阻塞性肺疾病中的使用情况[J].临床肺科杂志,2015,11(9):1684-1686.
[8]张向红.沙美特罗替卡松对照噻托溴铵联合沙美特罗替卡松治疗慢阻肺稳定期的观察[J].中国医药导刊,2012,8(11):445-447.
[9]曾林淼,俞晓莲,叶凯龙,等.沙美特罗替卡松联合噻托溴铵与单用沙美特罗替卡松治疗我国慢性阻塞性肺疾病患者的Meta分析[J].中国呼吸与危重监护杂志,2017,3(6):545-554.
[10]朱卫波.甲强龙联合多索茶碱对慢性阻塞性肺病患者血清脂联素、MMP-9、IL-17、IL-10及TNF-α水平的影响[J].海南医学院学报,2016,22(12):1214-1216.
[11]陈伦音,王颖峰,贺珊珊,等.参芪扶正注射液辅助纳洛酮与BiPAP呼吸机治疗对AECOPD伴Ⅱ型呼吸衰竭患者血清炎性因子、免疫功能及血气分析指标的影响[J].海南医学院学报,2017,23(16):2176-2179.
[12]张娟,左昔清,章建良,等.慢性阻塞性肺疾病合并呼吸衰竭患者Th1/Th2变化趋势及中医辨证治疗对其影响的研究[J].中华中医药学刊,2016,48(2):451-455.